Idorsia’s SchlafCollege Addresses Chronic Insomnia and Its Psychiatric Links
The first 2026 edition of Idorsia’s SchlafCollege, a medical education initiative for psychiatrists and neurologists, took place in Leipzig on February 27–28, focusing on the bidirectional relationship between chronic insomnia and psychiatric and neurological disorders, according to a press release. The event highlighted Daridorexant (QUVIVIQ®), a medication approved for long-term treatment of chronic insomnia, with real-world data suggesting potential benefits for comorbid conditions.
Chronic Insomnia and Comorbid Conditions
Chronic insomnia is closely linked to psychiatric and neurological disorders, with research indicating a bidirectional association, according to a 2023 review in the *Journal of Clinical Sleep Medicine*. Prof. Göran Hajak, a sleep medicine expert, emphasized during the SchlafCollege that chronic insomnia should be treated as an independent condition, even when co-occurring with other illnesses. “Long-term therapy is essential, particularly given the vulnerability and comorbidities of affected patients,” he stated.
Daridorexant’s Role in Insomnia Management
Daridorexant, a dual orexin receptor antagonist, has demonstrated efficacy and safety for chronic insomnia, regardless of comorbidities, per a 2022 study published in *The New England Journal of Medicine*. Real-world data also suggest it may positively impact psychiatric comorbidities, though further research is needed to confirm these effects. The drug is approved in the U.S. and European Union for adult patients.
Expert Insights and Clinical Implications
The SchlafCollege brought together specialists to discuss treatment strategies, with Hajak noting the importance of addressing insomnia as a standalone issue. “Its prevalence and impact on quality of life underscore the need for targeted, long-term interventions,” he said. Clinicians are advised to consider patient-specific factors when selecting therapies, balancing efficacy with safety profiles.
Future Directions in Sleep Medicine
As research on insomnia’s comorbidities evolves, the integration of treatments like Daridorexant into clinical practice remains a focus. Ongoing studies aim to clarify its role in managing psychiatric conditions, with experts urging continued collaboration between sleep medicine and mental health fields.
Key Takeaways
- Chronic insomnia is strongly linked to psychiatric and neurological disorders.
- Daridorexant offers a long-term treatment option for insomnia, with potential benefits for comorbid conditions.
- Experts stress the need for individualized, evidence-based approaches to insomnia management.
Related reading